{"id":"W2971414122","doi":"10.1016/s2213-8587(19)30256-6","title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","year":2019,"lang":"en","type":"review","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":870,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia","funders":"AstraZeneca; National Health and Medical Research Council; Verily Life Sciences; Medical Research Council; Bristol-Myers Squibb; Akebia Therapeutics; Gilead Sciences; Servier; Relypsa; Astellas Pharma; University of New South Wales; University of Oxford; MyoKardia; Novo Nordisk; ZOLL Medical Corporation; Janssen Pharmaceuticals; Ablynx; Sanofi; GlaxoSmithKline; Eli Lilly and Company; Boehringer Ingelheim; Amgen; Pfizer; Brigham and Women's Hospital","keywords":"Medicine; Empagliflozin; Albuminuria; Meta-analysis; Kidney disease; Dialysis; Kidney transplantation; Internal medicine; Renal function; Intensive care medicine; Diabetes mellitus; Type 2 diabetes; Transplantation; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05836797720339804,"score_gpt":0.3210231811762127,"score_spread":0.2626552039728147,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}